Overview

Overview
 
LeadArtis´s current business model includes the definition of an in-house pipeline and partnerships with other companies oriented to the combination of our technology with that of our collaborators.
 
Trimerbody® can be adapted to numerous protein configurations. There are multiple options to establish such relationships. Should you believe that our technology is of interest, we would be pleased to tell you more details and accommodate flexible avenues for collaboration schemes.  
 
 

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)
31-10-2017

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy
15-01-2018

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...